Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes.

but one of the conclusions of the pilot was that a pre-requisite for adoption will be "robust systems in place ensuring that the patient can easily access the package leaflet for their medicine in ...

The latest Herceptin biosimilar is branded as Kanjinti (trastuzumab-anns) and is approved in all indications of the reference product. These are for the treatment of HER2-overexpressing adjuvant ...

As of 2:14:44 p.m. EDT. Market Open. Loading Chart for AMGN ...